To better understand the burden of partial treatment response on schizophrenia patients, their caregivers, and health care resources, this study compared demographics, outcomes, and comorbidities among schizophrenia patients with treatment response.
Transdermal asenapine administration may address unmet needs in patients with schizophrenia, including improved adherence. This phase 3 study assessed efficacy and safety of HP-3070, an asenapine transdermal system (patch), in adults with schizophrenia.
Lockdown measures have helped contain the spread of COVID-19, but how do they affect mental health? This report describes a patient who developed a paranoid delusion caused by isolation, uncertainty, anxiety, and fear related to lockdown.
Cavum septi pellucidi (CSP) is significantly more prevalent in individuals with mental illness than in healthy subjects. This report presents 3 cases of CSP and temporal lobe epilepsy-related psychosis previously misdiagnosed as schizoaffective disorder.
In this commentary, the authors address the impact of COVID-19 on patients with schizophrenia based on multiaxial diagnostic criteria and comment on the use of technology, telehealth, and other available strategies to mitigate the effects.
Does the capacity to consent vary between medical and psychiatric patients? Are tools needed to assess the patient's decision-making capacity, or can the provider's assessment be relied upon? Review the results of a study that sought answers to these questions in this CME journal activity.
Long-acting injectable (LAI) antipsychotics improve adherence, reduce treatment gaps, and improve clinical outcomes. This report describes the long-term safety, tolerability, and symptom trajectory with the LAI antipsychotic aripiprazole lauroxil.
Clozapine has been associated with pneumonia, but what about other agents? This study compared pneumonia hospitalization rates for patients with a psychotic or bipolar disorder prescribed 1 of 4 second-generation antipsychotics prior to admission.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”